Research Agreement Template

In plain language: Identifies the sponsoring party and the performing party by full legal name, explains the background and purpose of the research relationship, and defines key terms used throughout the agreement.

Common mistake: Using informal names or abbreviations in the parties block instead of registered legal entity names. If the performing entity is a university department rather than the university itself, the wrong entity may be identified — creating an unenforceable agreement against the party that actually holds the IP.

In plain language: Describes the specific research to be conducted, referencing a detailed Statement of Work attached as a schedule, and clarifies what is explicitly out of scope.

Common mistake: Embedding the full scope in the body of the agreement rather than a separate Schedule A. When the SOW needs updating mid-project, an embedded scope requires a formal contract amendment — a separate schedule can be replaced without re-executing the entire agreement.

In plain language: Sets the start date, end date, and any interim milestone dates tied to deliverables or payment triggers.

Common mistake: Setting a single end date with no interim milestones for multi-year projects. Without checkpoints, a sponsor may fund a full year before discovering the project has deviated significantly from the agreed scope.

In plain language: States the total research budget, payment schedule tied to milestones or calendar dates, invoicing requirements, and what happens to unexpended funds if the project ends early.

Common mistake: Agreeing to a lump-sum payment due at project completion on a multi-year contract. If the agreement is terminated early, a lump-sum structure gives the researcher no payment for work completed and gives the sponsor no leverage to enforce milestone delivery.

In plain language: Determines who owns IP created during the project — foreground IP — and how background IP is treated. Specifies whether the sponsor receives an assignment, exclusive license, or option to license.

Common mistake: Failing to distinguish foreground IP from background IP. Without the distinction, a sponsor's assignment clause can inadvertently capture pre-existing tools, software, or know-how that the researcher uses across multiple projects — creating disputes or making the researcher unable to work with other clients.

In plain language: Defines what constitutes confidential information, how it may be used and stored, how long confidentiality obligations survive the agreement, and how research data is handled, transferred, and retained.

Common mistake: Setting a confidentiality term that expires at the same time as the agreement. Research findings — especially unpublished data — remain competitively sensitive for years after a project ends. A post-termination survival period of three to five years is standard practice.

In plain language: Grants the researcher the right to publish findings while giving the sponsor a review period to identify patentable inventions or remove confidential information before publication.

Common mistake: Granting the sponsor an unlimited or indefinite right to delay publication. Academic researchers are bound by institutional policies requiring eventual publication. An indefinite block can void the agreement at the university level and make recruitment of top researchers impossible.

In plain language: Each party warrants that it has authority to enter the agreement, that the research will comply with applicable laws and ethical guidelines, and that it holds the necessary rights to any background IP it contributes.

Common mistake: Omitting ethical compliance warranties for life sciences or human-subjects research. If a study later turns out to lack required IRB or ethics-board approval, the sponsor can face reputational damage, regulatory liability, and unusable data — none of which is recoverable without a warranty and indemnity in the contract.

In plain language: States the conditions under which either party may terminate — for cause, for convenience, or upon force majeure — and what happens to IP, data, deliverables, and payment obligations upon termination.

Common mistake: No termination-for-convenience clause for the sponsor. Research projects frequently need to be wound down when commercial priorities shift. Without a convenience termination right, a sponsor is locked into the full budget even if the strategic rationale disappears — or must negotiate a settlement.

In plain language: Specifies which jurisdiction's law governs, how disputes are resolved (arbitration, mediation, or litigation), and confirms the written agreement supersedes all prior discussions and letters of intent.

Common mistake: Choosing a governing law with no connection to where the research is actually performed. Several jurisdictions — including California and Quebec — apply mandatory local rules to contracts performed within their borders regardless of a contrary choice-of-law clause, particularly for employment and IP matters.

A research agreement is a legally binding contract between a sponsor — typically a company, government agency, or foundation — and a researcher or research institution that defines the scope of work, payment terms, IP ownership, confidentiality obligations, publication rights, and termination conditions for a specific research project. It protects both parties by creating clear, enforceable expectations before any work or confidential information is exchanged.

Any company commissioning external research — from universities, contract research organizations, independent scientists, or research consultants — needs a research agreement to secure IP rights and protect proprietary information. Universities and research institutions use them to formalize sponsored research arrangements and protect their researchers' publication rights. Two companies co-funding joint research also use research agreements to allocate ownership of jointly developed IP.

An NDA protects confidential information exchanged during discussions but does not govern the research relationship itself — it covers no scope of work, no IP assignment, and no payment. A research agreement includes confidentiality provisions and additionally covers all material terms of the research engagement. Use an NDA to protect information during initial negotiations, then replace it with a full research agreement once the parties decide to proceed.

IP ownership depends entirely on what the parties negotiate and document in the agreement. In a sponsored research arrangement, sponsors typically seek an assignment of all foreground IP — or at minimum an exclusive option to license it. Universities often resist outright assignment and prefer a royalty-bearing license. For joint research, IP may be jointly owned with each party having the right to exploit it independently. Without a written agreement, patent law defaults vary by jurisdiction — in the US, each named inventor owns an undivided share regardless of who funded the work.

It depends on the institution's IP policy. Most research universities claim ownership of IP developed by their faculty and staff using university resources. A faculty researcher typically cannot assign IP to a sponsor directly — the university technology-transfer office must be the contracting party and negotiate the assignment or license on the institution's behalf. Always confirm the institution's IP policy and involve the TTO before finalizing any research agreement with academic researchers.

Sponsors typically receive a review period of 30 to 60 days before a researcher may submit findings for publication, giving the sponsor time to identify patentable inventions and request removal of confidential information. An additional delay of up to 90 to 120 days for patent filing is common. Most university policies prohibit permanent publication suppression, so sponsors should not expect or request an indefinite block. The total delay is typically capped at 180 days in agreements with major research universities.

In most jurisdictions, IP licenses and research contracts are treated as executory contracts in bankruptcy proceedings. The bankruptcy trustee may assume or reject the agreement. If rejected, the researcher may be left with an unsecured claim for unpaid amounts and may lose the benefit of any IP assignment that has not yet been recorded. To reduce exposure, researchers should insist on milestone payments rather than backend-loaded compensation, and consider requesting that any IP assignment be recorded with the patent office promptly upon execution.

Notarization is generally not required for a research agreement to be legally enforceable in the US, Canada, the UK, or the EU. Both parties' authorized signatures are sufficient. However, some patent offices recommend or require a formal written assignment document — separate from the research agreement — to be recorded when transferring patent rights. Confirm the recording requirements of the relevant patent office for any jurisdiction where protection is sought.

Three to five years post-termination is standard for most research agreements. For agreements involving trade secrets, novel compounds, or unpublished clinical data, a longer period — up to ten years or the life of any resulting patent — may be warranted. Indefinite confidentiality obligations are enforceable in many jurisdictions for true trade secrets but can be difficult to defend for general research know-how. Match the survival period to the commercial sensitivity of the specific information involved.